BEIJING, Oct. 8, 2012 /PRNewswire/ -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, was recently listed as one of the Deloitte & Touche's 50 top-performing Chinese high-tech companies which rides on high growth for 2012, the second time the company won the honor after it got the award for the first time in 2011.

Beijing-headquartered GC-Rise, which focuses on women's health in China, was the only pharmaceutical company to receive the award, with most others engaged in software and e-commerce business.

An awards ceremony was held in Beijing on Sept. 20, where GC-Rise's executives shared the company's legacy with participants.

GC-Rise, founded in 2008, has saw rapid increase in revenues over 4 years' expansion, with revenues up 172 percent year-on-year in 2011, and it surged 209 percent at the end of August, 2012, compared with same period of last year.

The Company's rapid growth was backed by booming target market, premium products as well as efficient management team.

The enrollment in the top 50 by Deloitte shows that GC-Rise's focus on the women's niche market has born fruits, with growth momentum gathering pace despite of the country's economic slow-down.

About Deloitte & Touche's Top 50

The rating of the top 50 Chinese companies initiated by Deloitte & Touche, which focuses on high-tech, media and telecom industries, are based on core criteria of annual operating revenues growth rate over the past three years rather than assets expansion. Those enrolled in the list are qualified to contend for top 500 in Asia Pacific.

About GC-Rise Pharmaceutical Co. Ltd

GC-Rise Pharmaceutical Co. Ltd, established in 2008, is a wholly-owned foreign enterprise invested by INVENTAGES, a major European healthcare and biotechnology venture capital investor, focuses on women's health. Taking "Devoted to human healthcare and a better life" as our mission, the company makes full use of the business networks of our strategic partners in the United States, Europe and Japan, their rich experiences in clinical development, clinical trials and registration in China and their strong strength in distributions, hospital sales and marketing, so as to provide safe, novel and highly efficient medical products and treatment ideas for Chinese women patients.